Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr;32(2):99-107.
doi: 10.1177/09727531231198298. Epub 2023 Nov 7.

A Longitudinal Two-Armed Randomized Controlled Trial Protocol to Evaluate the Efficacy of Yoga on Progression of Disease in Early Parkinson's Disease

Parameshwar Some  1 , Vijaya Majumdar  1 , Manjunath N K  1 , Kuldeep Shetty  2 , Atmakur Snigdha  1
Affiliations

A Longitudinal Two-Armed Randomized Controlled Trial Protocol to Evaluate the Efficacy of Yoga on Progression of Disease in Early Parkinson's Disease

Parameshwar Some et al. Ann Neurosci. 2025 Apr.

Abstract

Background: Numerous studies have shown that yoga can aid patients with Parkinson's disease (PD) in managing their motor function, functional mobility, balance, anxiety, and overall quality of life. However, most of the reported research either needed more power or evaluated the results during or after the intervention. Due to the long-standing nature of PD, there are still few longitudinal studies investigating the potential of yoga to decrease the progression of the disease.

Purpose: We study whether sustained adjunct yoga intervention slows PD progression.

Methods: Over 18 months, this study will investigate the long-term benefits of yoga-based intervention in Parkinson's patients. The concept of "intention-to-treat (ITT)" will be employed. From the outpatient clinic of the Swami Vivekananda Yoga Anusandhana Samsthana in India, 160 patients with PD will be chosen. They will then be randomly assigned to either the interventional or control groups (1:1). The adjunct intervention group will participate in 21 daily contact yoga sessions (60 min) at the University Medical Center, followed by continued tele-supervised home practice and at-home self-practice. The effectiveness of the adjunct intervention will be evaluated at four different time points (baseline, 3-, 9-, 12-, and 18-month post-randomization). The primary endpoint will be the difference in the Movement Disorder Society-Unified Parkinson Disease Rating Scale (MDS-UPDRS) Part III score at baseline and after 18 months of intervention. Secondary outcomes will include subscores of MDS-UPDRS I, II, and IV, Parkinson's Disease Questionnaire (PDQ)-39 scores, treatment adherence, the PDQ-39, the Depression, Anxiety, and Stress Scale-21, and the Scales for Outcomes in PD-Sleep Scale (SCOPA-S). The primary outcome will be analyzed using mixed-effect models for repeated measures, adjusted for covariates as fixed effects.

Results: The protocol was conceptualized in October 2021 and approved by the Institutional Ethics Committee of SVYASA. Recruitment began in February 2022 and is underway with patient enrollment.

Conclusion: To our knowledge, this is the first controlled study to examine the long-term effects of yoga as an adjuvant therapy on the progression of PD.

Key message: This would be the first long-term trial to assess the potential of an adjunct yoga intervention to modulate disease progression in early Parkinson's patients.

Keywords: Clinical neuroscience; Parkinson’s disease; clinical trials; yoga.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.. Participant Flow Chart for Parallel Design, Based on the CONSORT Guidelines for Transparent Reporting of Trials.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Dorsey ER and Bloem BR.. The Parkinson pandemic-A call to action. JAMA Neurol 2018 ; 75: 9–10. https://doi.org/10.1001/jamaneurol.2017.3299 - PubMed
    1. Calabrese VP. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007; 69(2): 223–224. https://doi.org/10.1212/01.wnl.0000271777.50910.73 - PubMed
    1. Maiti P, Manna J, and Dunbar GL.. Current understanding of the molecular mechanisms in Parkinson’s disease: targets for potential treatments. Transl Neurodegener 2017; 6: 28. https://doi.org/10.1186/s40035-017-0099-z - PMC - PubMed
    1. Perlmutter JS. Assessment of Parkinson disease manifestations. Curr Protoc Neurosci 2009; Chapter 10: Unit 10.1. https://doi.org/10.1002/0471142301.ns1001s49 - PMC - PubMed
    1. Fox SH, Katzenschlager R, Lim SY, et al.. International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 2018; 33(8): 1248–1266. https://doi.org/10.1002/mds.27372 - PubMed